Glenmark Specialty SA has received approval from the U.S. FDA for fluticasone propionate inhalation aerosol USP, 44 mcg per actuation. The FDA says the treatment is the first generic of Flovent HFA, manufactured by GSK, for maintenance of asthma. Glenmark plans to begin distributing the treatment, which deepens its respiratory portfolio, in the U.S. in March 2026. Due to the approval, a Competitive Generic Therapy (CGT) designation, Glenmark will get 180 days of CGT exclusivity at commerciali...